Jailendra Singh
Stock Analyst at Truist Securities
(0.91)
# 3,548
Out of 4,814 analysts
168
Total ratings
27.27%
Success rate
-26.03%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Hold | $347 → $333 | $296.28 | +12.39% | 3 | Apr 10, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $263 → $216 | $143.91 | +50.09% | 15 | Apr 10, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $262 → $208 | $139.30 | +49.32% | 9 | Apr 10, 2025 | |
| PRVA Privia Health Group | Maintains: Buy | $27 → $28 | $23.68 | +18.24% | 7 | Apr 10, 2025 | |
| HIMS Hims & Hers Health | Maintains: Hold | $39 → $33 | $27.22 | +21.23% | 9 | Apr 10, 2025 | |
| GDRX GoodRx Holdings | Maintains: Hold | $6.5 → $5.5 | $4.48 | +22.91% | 12 | Apr 10, 2025 | |
| EVH Evolent Health | Maintains: Buy | $15 → $14 | $8.97 | +56.08% | 5 | Apr 10, 2025 | |
| DOCS Doximity | Maintains: Hold | $65 → $58 | $53.20 | +9.02% | 7 | Apr 10, 2025 | |
| AMWL American Well | Maintains: Hold | $12 → $7.5 | $6.99 | +7.30% | 7 | Apr 10, 2025 | |
| ASTH Astrana Health | Maintains: Buy | $50 → $46 | $31.35 | +46.73% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $36.44 | +23.49% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $261 → $210 | $220.66 | -4.83% | 7 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $34 | $23.94 | +42.02% | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $26 → $19 | $21.44 | -11.38% | 9 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $10 | $6.83 | +46.41% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $11.14 | +25.67% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $4.00 | +62.70% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $5.91 | +120.15% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $43 | $6.65 | +546.62% | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $2.53 | +850.50% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $3.24 | +23.46% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $134.68 | -56.93% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $11.22 | +301.07% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $697.08 | -52.23% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $3.60 | +150.00% | 2 | May 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $19.45 | - | 3 | Jan 15, 2021 |
Medpace Holdings
Apr 10, 2025
Maintains: Hold
Price Target: $347 → $333
Current: $296.28
Upside: +12.39%
IQVIA Holdings
Apr 10, 2025
Maintains: Buy
Price Target: $263 → $216
Current: $143.91
Upside: +50.09%
ICON Public Limited Company
Apr 10, 2025
Maintains: Buy
Price Target: $262 → $208
Current: $139.30
Upside: +49.32%
Privia Health Group
Apr 10, 2025
Maintains: Buy
Price Target: $27 → $28
Current: $23.68
Upside: +18.24%
Hims & Hers Health
Apr 10, 2025
Maintains: Hold
Price Target: $39 → $33
Current: $27.22
Upside: +21.23%
GoodRx Holdings
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $4.48
Upside: +22.91%
Evolent Health
Apr 10, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $8.97
Upside: +56.08%
Doximity
Apr 10, 2025
Maintains: Hold
Price Target: $65 → $58
Current: $53.20
Upside: +9.02%
American Well
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $6.99
Upside: +7.30%
Astrana Health
Mar 18, 2025
Maintains: Buy
Price Target: $50 → $46
Current: $31.35
Upside: +46.73%
Mar 14, 2025
Initiates: Buy
Price Target: $45
Current: $36.44
Upside: +23.49%
Jan 13, 2025
Maintains: Hold
Price Target: $261 → $210
Current: $220.66
Upside: -4.83%
Dec 11, 2024
Maintains: Buy
Price Target: $31 → $34
Current: $23.94
Upside: +42.02%
Nov 13, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $21.44
Upside: -11.38%
Aug 2, 2024
Maintains: Hold
Price Target: $15 → $10
Current: $6.83
Upside: +46.41%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $11.14
Upside: +25.67%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $4.00
Upside: +62.70%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $5.91
Upside: +120.15%
Feb 28, 2022
Maintains: Neutral
Price Target: $42 → $43
Current: $6.65
Upside: +546.62%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $2.53
Upside: +850.50%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $3.24
Upside: +23.46%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $134.68
Upside: -56.93%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $11.22
Upside: +301.07%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $697.08
Upside: -52.23%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $3.60
Upside: +150.00%
Jan 15, 2021
Downgrades: Underperform
Price Target: n/a
Current: $19.45
Upside: -